Sodium chloride is already familiar across global respiratory self-care. BREATHOX® builds on that foundation through a differentiated, protected dry-powder treatment modality.

LIITA works with selected commercial, clinical, scientific and institutional partners to expand the reach and evidence base of the technology.

Commercial partners can contribute market access, consumer-health expertise, healthcare-professional reach and regulatory capabilities. Clinical and scientific partners strengthen the evidence base, while selected institutional relationships support credible new applications.

We prioritise meaningful capabilities while preserving the coherence of the technology, evidence, intellectual property and brand platform.

For strategic partnership enquiries, contact Martin Ohrt, CEO & Founder.